Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: Analysis of the Cardiac Arrhythmia Suppression Trial

Journal of the American College of Cardiology

Volumn 25, Issue 6, 1995, Pages 1250-1257

  Hallstrom, Al ^a,c   Pratt, Craig M ^a,c   Leon Greene, H ^a,c   Huther, Melissa ^a,c   Gottlieb, Stephen ^b,c   DeMaria, Anthony ^c,d   Young, James B ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENCAINIDE;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HEART ARRHYTHMIA; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS;

ARRHYTHMIA; ELECTROCARDIOGRAPHY; ENCAINIDE; FEMALE; FLECAINIDE; HEART FAILURE, CONGESTIVE; HUMAN; MALE; MIDDLE AGE; MORICIZINE; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; STROKE VOLUME; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL ANALYSIS;

EID: 0028906168     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(94)00553-3     Document Type: Article

References (25)

1. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction
2. Ventricular premature complexes and sudden death after myocardial infarction
3. Ventricular premature beats and mortality after myocardial infarction
4. Risk stratification and survival after myocardial infarction
5. Sudden death in the year following myocardial infarction relation to ventricular premature contractions in the late hospital phase and left ventricular ejection fraction
6. Arrhythmias and mortality in congestive heart failure
7. Avoiding interpretive pitfalls when assessing arrhythmia suppression after myocardial infarction: insights from the long-term observations of the placebo-treated patients in Cardiac Arrhythmia Pilot Study (CAPS)
8. Preliminary report effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
9. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction—the original design concept of the Cardiac Arrhythmia Suppression Trial (CAST)
10. Classification of deaths after myocardial infarction as arrhythmic or nonarrhythmic (the Cardiac Arrhythmia Pilot Study)
11. Nonparametric estimation from incomplete observations
12. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction: a possible explanation for the increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST)
13. A statistical problem arising from retrospective studies
14. Regression models and life tables (with discussion)
15. Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in patients surviving open label titration but not randomized to double-blind therapy
16. Relation of acute antiarrhythmic drug efficacy to left ventricular function in coronary artery disease
17. The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: a dangerous imbalance in the risk-benefit ratio
18. Predictors of antiarrhythmic drug efficacy in patients with malignant ventricular tachyarrhythmias
19. Effects of encainide flecainide imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction the CAPS
20. Prognosis in severe heart failure: relation to hemodynamic measurements and ventricular ectopic activity
21. Factors influencing survival and mode of death in severe chronic ischaemic cardiac failure
22. Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure
23. The prognosis in the presence of coronary artery disease
24. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, venticular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure